炎症性肠病 (IBD) 是一种慢性免疫介导性疾病，其特点是由于无法控制的炎症引起的重要肠道组织损伤。抗炎治疗已有所改善，但目前还没有适用于组织修复的方法。器官样本已发展成为研究人类疾病机制的强大实验平台。在这里，我们专门关注器官样本在直接组织修复对抗 IBD 中的作用。我们讨论了此项治疗方法的科学原理、科学技术的最新进展 (CRISPR / Cas9 和代谢编程)，以及在此治疗方法可行的临床 IBD 背景。最后，我们回顾了器官样本应用的转化路线，并强调了这是 IBD 中新方向的必要性。© 2023 Crohn's＆Colitis Foundation。由牛津大学出版社代表 Crohn's＆Colitis Foundation 发布。

Inflammatory bowel diseases (IBDs) are chronic immune-mediated conditions characterized by significant gut tissue damage due to uncontrolled inflammation. Anti-inflammatory treatments have improved, but there are no current prorepair approaches. Organoids have developed into a powerful experimental platform to study mechanisms of human diseases. Here, we specifically focus on its role as a direct tissue repair modality in IBD. We discuss the scientific rationale for this, recent parallel advances in scientific technologies (CRISPR [clustered regularly interspaced short palindromic repeats]/Cas9 and metabolic programming), and in addition, the clinical IBD context in which this therapeutic approach is tractable. Finally, we review the translational roadmap for the application of organoids and the need for this as a novel direction in IBD.© 2023 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation.